KIM, YONG ZU,金容柱,金容柱,PARK, YUN HEE,朴允姬,朴允姬,CHOI, HYO JUNG,崔孝汀,崔孝汀,JUNG, JI EUN,郑智恩,鄭智恩,RYU, JEONG HEE,柳丁熙,柳丁熙,SONG, HO YOUNG,宋昊永,宋昊永,CHUNG, CHUL-WOONG,郑哲雄,鄭哲雄,CHAE, JEIWOOK,蔡济旭,蔡濟旭
申请号：
TW105131121
公开号：
TW201722480A
申请日:
2016.09.26
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor ("EGFR") antibody a linker and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime,e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.在一些態樣中,本發明係關於抗體-藥物共軛物,其包含抗表皮生長因子受體(「EGFR」)抗體、連接體及活性劑。該抗體-藥物共軛物可包含自消性基團。該連接體可包含O-取代之肟,例如,其中該肟之氧原子經將該肟共價連接至該藥物之基團取代;且該肟之碳原子經將該肟共價連接至該抗體之基團取代。
